Alexandra Ramsey's questions to Viking Therapeutics Inc (VKTX) leadership • Q3 2024
Question
Alexandra Ramsey asked about the company's philosophical approach to dosing VK2735 in a weight maintenance setting versus an active weight-loss phase. She also inquired about Viking's perspective on the optimal agonism ratio between amylin and calcitonin for its new dual agonist program.
Answer
Brian Lian, an executive, explained that the monthly dosing regimen is primarily envisioned for weight maintenance, offering convenience after a target weight is achieved. On the amylin program, he noted that while the ideal ratio is not fully understood, their research suggests a more balanced agonism on both amylin and calcitonin receptors appears to provide a better overall weight loss profile.